title: Complications following thiacetarsamide sodium therapy in Louisiana dogs with naturally-occurring heartworm disease.
abstract: Four hundred and sixteen dogs with naturally-occurring heartworm disease were evaluated for complications following thiacetarsamide sodium therapy. Of these, 109 dogs (26.2%) experienced complications. Increased lung sounds was the most commonly seen complication, followed by fever and coughing. In dogs with complications, 83.5% of them presented without clinical evidence of pulmonary thromboembolism or heart failure. There were no statistically significant differences between the age, sex, breed and body size of dogs that experienced complications following thiacetarsamide therapy and dogs that did not. Complications were most frequently seen 5 to 9 days following thiacetarsamide therapy although some dogs experienced initial complications as late as 28 days. Thirty-three of 109 dogs (33.0%) with complications responded to exercise restriction. The remaining 76 dogs with complications prior to or following thiacetarsamide required adjunct drug therapy. Of these, 35 dogs responded favorably to anti-inflammatory doses of prednisolone or prednisone. Five dogs died or were euthanatized because of the complications experienced. Eighteen of 416 dogs (4.3%) presented with clinical evidence of pulmonary thromboembolism or heart failure prior to the thiacetarsamide therapy. All 18 dogs experienced complications in spite of adjunct drug therapy and exercise restriction prior to, during, and following thiacetarsamide therapy. Survival rate following resolution of the thiacetarsamide-induced complications was greater than 98%.
mesh_terms: D000367:Age Factors; D000818:Animals; D001148:Arsenamide / Q000009:adverse effects* / Q000627:therapeutic use; D001152:Arsenicals / Q000009:adverse effects*; D001835:Body Weight; D004184:Dirofilariasis / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D008297:Male; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000662:veterinary; D012737:Sex Factors
chemical_list: D001152:Arsenicals; D001148:Arsenamide